Skip to Content
Morningstar

Genmab A/S GMAB

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 1,755.00 +17.00 (0.98%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Strong Royalty Revenue From Darzalex Continues to Drive Growth for Narrow-Moat Genmab

Rachel Elfman

Genmab is focused on the development of monoclonal antibody and bispecific antibody therapies in oncology indications. The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is now entrenched in multiple myeloma care for several lines of therapy, including the frontline setting. Additionally, Darzalex is often used in combination treatments, unlocking even greater market potential. Genmab receives royalties of up to 20% from J&J on Darzalex sales, plus milestones from the company's antibody platform partnerships.

Read Full Report

Price vs Fair Value

View History
GMAB is trading at a 488% premium.
Price
DKK 1,755.00
Fair Value
DKK 4,515.00
Uncertainty
Medium
1-Star Price
DKK 7,977.60
5-Star Price
DKK 7,425.00
Economic Moat
Nzmcvk
Capital Allocation
Vxbfyzbbm

Bulls Say, Bears Say

Bulls

Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

Bears

The multiple myeloma market is crowded with other molecules, including immunomodulatory drugs, proteasome inhibitors, HDAC inhibitors, and other targeted therapies.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GMAB is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
DKK 1,738.00
Day Range
DKK 1,737.50–1,763.50
52-Week Range
DKK 1,691.00–2,814.00
Bid/Ask
DKK 1,751.00 / DKK 1,751.50
Market Cap
DKK 111.38 Bil
Volume/Avg
83,737 / 140,993

Key Statistics

Price/Earnings (Normalized)
20.44
Price/Sales
6.45
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
0.51%

Company Profile

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
2,266
Website
https://www.genmab.com

Competitors

Valuation

View More
Metric
GMAB
4502
INCY
Price/Earnings (Normalized)
 20.4416.1015.11
Price/Book Value
 3.480.922.39
Price/Sales
 6.451.573.44
Price/Cash Flow
 17.057.6916.56
Price/Earnings
GMAB
4502
INCY

Financial Strength

Metric
GMAB
4502
INCY
Quick Ratio
 12.420.513.29
Current Ratio
 12.461.113.47
Interest Coverage
 216.181.35333.13
Quick Ratio
GMAB
4502
INCY

Profitability

Metric
GMAB
4502
INCY
Return on Assets (Normalized)
 15.15%5.19%13.25%
Return on Equity (Normalized)
 16.99%11.01%17.32%
Return on Invested Capital (Normalized)
 14.01%7.28%14.51%
Return on Assets
GMAB
4502
INCY
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
VhrwzsdpnmKtvq$628.7 Bil
 Vertex Pharmaceuticals Inc
VRTX
WmxnbnjXgdhx$122.5 Bil
 Regeneron Pharmaceuticals Inc
REGN
CvtrdqjfQdbhp$114.0 Bil
 Moderna Inc
MRNA
QqsnnkvpDrpg$45.3 Bil
 Alnylam Pharmaceuticals Inc
ALNY
GnqlqttmMkppj$31.8 Bil
 argenx SE ADR
ARGX
PsrtrvfxBmmlv$25.9 Bil
 BioNTech SE ADR
BNTX
NlkttmbBzsts$19.3 Bil
 Biomarin Pharmaceutical Inc
BMRN
CwfypjxMsstwm$15.5 Bil
 United Therapeutics Corp
UTHR
MhtgpfzbCrlt$14.0 Bil
 Royalty Pharma PLC Class A
RPRX
WkmdcxtfmXydrszx$11.6 Bil

Sponsor Center